| Drug General Information |
| Drug ID |
D01MUU
|
| Former ID |
DNC006574
|
| Drug Name |
MELAGATRAN
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 3 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H31N5O4
|
| InChI |
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
|
| InChIKey |
DKWNMCUOEDMMIN-PKOBYXMFSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
823967, 823976, 7888877, 10260002, 12015035, 14807481, 14832162, 33506196, 46392332, 49973260, 51091482, 75448641, 81054817, 87225413, 103986867, 104234149, 104440513, 127347174, 127347175, 135161591, 137220555, 137237552, 139272419, 160657372, 162169159, 163125710, 164228525, 164761749, 176225277, 178103000, 180372434, 198939790, 204369753, 215780616, 223554840, 226415180, 247111512
|
| SuperDrug ATC ID |
B01AE04
|
| Target and Pathway |
| Target(s) |
Coagulation factor IIa |
Target Info |
Inhibitor |
[3]
|
|---|
| Plasminogen |
Target Info |
Inhibitor |
[4]
|
| Trypsin |
Target Info |
Inhibitor |
[4]
|
| Coagulation factor Xa |
Target Info |
Inhibitor |
[4]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Complement and coagulation cascades
|
|
Regulation of actin cytoskeletonhsa04080:Neuroactive ligand-receptor interaction
|
|
Staphylococcus aureus infection
|
|
Influenza Ahsa04080:Neuroactive ligand-receptor interaction
|
|
Pancreatic secretion
|
|
Protein digestion and absorption
|
|
Influenza Ahsa04610:Complement and coagulation cascades
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulationP00011:Blood coagulation
|
|
Plasminogen activating cascadeP00011:Blood coagulation
|
|
Pathway Interaction Database
|
Thrombin/protease-activated receptor (PAR) pathway
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
FOXA2 and FOXA3 transcription factor networks
|
|
PAR4-mediated thrombin signaling events
|
|
Syndecan-4-mediated signaling events
|
|
PAR1-mediated thrombin signaling eventsangiopoietinreceptor_pathway:Angiopoietin receptor Tie2-mediated signaling
|
|
p75(NTR)-mediated signaling
|
|
amb2 Integrin signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingintegrin2_pathway:Beta2 integrin cell surface interactions
|
|
PathWhiz Pathway
|
Vitamin K Metabolism
|
|
CoagulationPW000562:CoagulationPW000562:Coagulation
|
|
Reactome
|
Intrinsic Pathway of Fibrin Clot Formation
|
|
Common Pathway of Fibrin Clot Formation
|
|
Gamma-carboxylation of protein precursors
|
|
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
|
|
Removal of aminoterminal propeptides from gamma-carboxylated proteins
|
|
Cell surface interactions at the vascular wall
|
|
Peptide ligand-binding receptors
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
G alpha (q) signalling events
|
|
Thrombin signalling through proteinase activated receptors (PARs)R-HSA-114608:Platelet degranulation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Dissolution of Fibrin ClotR-HSA-1592389:Activation of Matrix Metalloproteinases
|
|
Cobalamin (Cbl, vitamin B12) transport and metabolismR-HSA-140834:Extrinsic Pathway of Fibrin Clot Formation
|
|
WikiPathways
|
Complement and Coagulation Cascades
|
|
Regulation of Actin Cytoskeleton
|
|
IL1 and megakaryotyces in obesity
|
|
Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
PTM: gamma carboxylation, hypusine formation and arylsulfatase activation
|
|
Blood Clotting Cascade
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Thrombin signalling through proteinase activated receptors (PARs)
|
|
Platelet Aggregation (Plug Formation)
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Formation of Fibrin Clot (Clotting Cascade)
|
|
Cell surface interactions at the vascular wall
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient NetworkWP558:Complement and Coagulation Cascades
|
|
Human Complement System
|
|
Activation of Matrix Metalloproteinases
|
|
Dissolution of Fibrin Clot
|
|
Selenium Micronutrient NetworkWP2769:Activation of Matrix MetalloproteinasesWP558:Complement and Coagulation Cascades
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00206089) Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6382). |
|---|
| REF 3 | Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. Epub 2006 Feb 3.Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. |
|---|
| REF 4 | Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. Epub 2006 Mar 6.Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. |
|---|
